Literature DB >> 10964445

Comparison of the inactivation of canine and bovine parvovirus by freeze-drying and dry-heat treatment in two high purity factor VIII concentrates.

P L Roberts1, H Hart.   

Abstract

The inactivation of bovine parvovirus (BPV) and canine parvovirus (CPV) by freeze-drying and terminal dry-heat treatment at 80 degrees C for 72 h has been investigated in two high purity factor VIII concentrates. In one product, CPV was slightly more resistant to freeze-drying compared to BPV, i.e. 0.7 vs. 1.4 log. However, BPV was substantially more resistant to heat-treatment compared to CPV, i.e. 1.3 vs. > 3.1 log inactivation after 72 h at 80 degrees C. In a second product, CPV was also slightly more resistant to freeze-drying than BPV, i.e. 0.2 vs. 1.3 log inactivation. However, heat-treatment gave essentially similar inactivation for both viruses, i.e. 2.8-3.4 log after 72 h at 80 degrees C. In conclusion, the resistance of these parvovirus models is dependent both on the type of virus and on the specific product involved. Copyright 2000 The International Association for Biologicals.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10964445     DOI: 10.1006/biol.2000.0256

Source DB:  PubMed          Journal:  Biologicals        ISSN: 1045-1056            Impact factor:   1.856


  5 in total

1.  New Parvovirus Associated with Serum Hepatitis in Horses after Inoculation of Common Biological Product.

Authors:  Thomas J Divers; Bud C Tennant; Arvind Kumar; Sean McDonough; John Cullen; Nishit Bhuva; Komal Jain; Lokendra Singh Chauhan; Troels Kasper Høyer Scheel; W Ian Lipkin; Melissa Laverack; Sheetal Trivedi; Satyapramod Srinivasa; Laurie Beard; Charles M Rice; Peter D Burbelo; Randall W Renshaw; Edward Dubovi; Amit Kapoor
Journal:  Emerg Infect Dis       Date:  2018-02       Impact factor: 6.883

2.  Viral testing of 18 consecutive cases of equine serum hepatitis: A prospective study (2014-2018).

Authors:  Joy E Tomlinson; Amit Kapoor; Arvind Kumar; Bud C Tennant; Melissa A Laverack; Laurie Beard; Katie Delph; Elizabeth Davis; Harold Schott Ii; Kara Lascola; Todd C Holbrook; Philip Johnson; Sandra D Taylor; Erica McKenzie; Jessica Carter-Arnold; Emilie Setlakwe; Lisa Fultz; Jeff Brakenhoff; Rebecca Ruby; Sheetal Trivedi; Gerlinde R Van de Walle; Randall W Renshaw; Edward J Dubovi; Thomas J Divers
Journal:  J Vet Intern Med       Date:  2018-12-05       Impact factor: 3.333

Review 3.  Virus safety of intravenous immunoglobulin: future challenges.

Authors:  Nicola Boschetti; Martin Stucki; Peter J Späth; Christoph Kempf
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

4.  Safety of snake antivenom immunoglobulins: efficacy of viral inactivation in a complete downstream process.

Authors:  C P Caricati; L Oliveira-Nascimento; J T Yoshida; A T P Caricati; I Raw; M A Stephano
Journal:  Biotechnol Prog       Date:  2013-06-27

5.  Tropism, pathology, and transmission of equine parvovirus-hepatitis.

Authors:  Joy Ellen Tomlinson; Mason Jager; Alyssa Struzyna; Melissa Laverack; Lisa Ann Fortier; Edward Dubovi; Lane D Foil; Peter D Burbelo; Thomas J Divers; Gerlinde R Van de Walle
Journal:  Emerg Microbes Infect       Date:  2020-03-20       Impact factor: 7.163

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.